Hemispherx Biopharma

$HEB The official corporate Twitter feed for Hemispherx Biopharma, Inc., an advanced specialty pharmaceutical company.

[Hemispherx Biopharma @HemispherxBio]

Hemispherx Biopharma, Inc. Changes Name to AIM ImmunoTech Inc. Reflecting Ampligen's® Immuno Modulation Progress in Ongoing Oncology Clinical Trials and ME/CFS https://t.co/YiUdgwjocf

[Hemispherx Biopharma @HemispherxBio]

Hemispherx Issues 2019 Second Quarter Report Citing Strong Steady Progress in Cancer Clinical Trials https://t.co/14Bbenfnwk

[Hemispherx Biopharma @HemispherxBio]

Hemispherx Reports Positive Safety and Survival Data in Phase 1 Stage 4 Ovarian Cancer Clinical Study Using Ampligen https://t.co/k1ZNnO8dzX

[Hemispherx Biopharma @HemispherxBio]

VIDEO Update: Hemispherx Biopharma, Inc. (NYSE MKT: HEB) https://t.co/a2JLxLn7Ba

[Hemispherx Biopharma @HemispherxBio]

Hemispherx Biopharma CFO Adam Pascale Announces Retirement https://t.co/iR2IF7WdlB

[Hemispherx Biopharma @HemispherxBio]

Hemispherx Biopharma Issues Clinical Update for Ampligen Immuno-oncology Program https://t.co/XaqM64rgDi

[Hemispherx Biopharma @HemispherxBio]

Ovarian Cancer News Today Updates Readers on Ampligen Trials https://t.co/YItkAeJ3iA

[Hemispherx Biopharma @HemispherxBio]

Hemispherx Reports 2019 First Quarter Financial Results https://t.co/EIdFH9oPDI

[Hemispherx Biopharma @HemispherxBio]

Hemispherx Announces Progress Toward Opening of Prostate Cancer Study at Roswell Park Comprehensive Cancer Center https://t.co/GtOj6ClftT

[Hemispherx Biopharma @HemispherxBio]

Hemispherx Links Stanford's ME/CFS Diagnostic to a Potential Path Forward for Ampligen Commercialization https://t.co/CfHzKWcj2T

[Hemispherx Biopharma @HemispherxBio]

$HEB Hemispherx BioPharma reports positive results on ovarian cancer treatment https://t.co/PgWmRiLHPe via @proactive_NA @HemispherxBio #HEB #brighterir #AndrewScottTV #CapitalNetwork1

[Hemispherx Biopharma @HemispherxBio]

Hemispherx Biopharma Announces Significant Progress in its Ampligen Ovarian Cancer Program https://t.co/9LHH3UNY0t

[Hemispherx Biopharma @HemispherxBio]

Hemispherx Biopharma's CEO to Present at Planet MicroCap Showcase 2019 https://t.co/DlVtMQj14c

[Hemispherx Biopharma @HemispherxBio]

Hemispherx Biopharma doses first patient with Ampligen in Phase 1 advanced breast cancer study https://t.co/A61OqefXjV

[Hemispherx Biopharma @HemispherxBio]

$HEB Hemispherx Biopharma updates on current trials, gears up to begin 5 more https://t.co/TNvMcQ5ZAC via @proactive_NA @HemispherxBio #HEB #brighterir #AndrewScottTV #CapitalNetwork1

[Hemispherx Biopharma @HemispherxBio]

Hemispherx Biopharma Announces Key Dates and Timeline for Stockholder Participation in Rights Offering https://t.co/KTRyGFkdH4

[Hemispherx Biopharma @HemispherxBio]

Hemispherx Biopharma's CEO to Present at the 15th Annual NobleConXV Conference https://t.co/VNtQb1fOzH

[Hemispherx Biopharma @HemispherxBio]

$HEB Hemispherx Biopharma's cancer drug Ampligen to be used in new oncology study https://t.co/YWN6ZXWIJm via @proactive_NA @HemispherxBio #HEB #brighterir #AndrewScottTV #CapitalNetwork1

[Hemispherx Biopharma @HemispherxBio]

Hemispherx (NYSE:HEB) Starting Two New Clinical Trials and Major US Cancer Centers https://t.co/Z8osVS10dx via @CEORoadShow

[Hemispherx Biopharma @HemispherxBio]

https://t.co/UUHKwnONjw